Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis., and ureaplasma Urealyticum to a new quinolone, trovafloxacin (CP-99,219)

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 4, 1996, Pages 1048-1049

  Kenny, George E ^a   Cartwright, Frank D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OFLOXACIN; SPARFLOXACIN; TROVAFLOXACIN;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; BACTERIUM CULTURE; BACTERIUM ISOLATION; MYCOPLASMA HOMINIS; MYCOPLASMA PNEUMONIAE; NOTE; PRIORITY JOURNAL; UREAPLASMA UREALYTICUM;

ANTI-INFECTIVE AGENTS; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; MYCOPLASMA; MYCOPLASMA PNEUMONIAE; NAPHTHYRIDINES; OFLOXACIN; QUINOLONES; UREAPLASMA UREALYTICUM;

EID: 0029868018     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.4.1048     Document Type: Article

References (11)

1. Domagala, J. M. 1994. Structure-activity and structure-side-effect relationships for the qumolone antibacterials. J. Antimicrob. Chemother. 33:685-706.
2. Eliopoulos, G. M., K. Klimm, C. T. Eliopoulos, M. J. Ferraro, and R. C. Moellering. 1993. In vitro activity of CP-99,219. a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrob. Agents Chemother. 37:366-370.
3. Gootz, T. D., K. E. Brighty, M. R. Anderson, B. J. Schmieder, S. L. Haskell, J. A. Suteliffe, M. J. Castaldi, and P. R. McGuirk. 1994. In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3,1,0]hexyl]napthyridone antimicrobial Diagn. Microbiol. Infect. Dis. 19:234-243
4. Kaku, M., K. Ishida, K. Irifune, R. Mizukane, H. Takemura, R. Yoshida, H. Tanaka, T. Usui, K. Tomono, N. Suyama, H. Koga, S. Kohno, and K. Hara. 1994 In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae. Antimicrob. Agents Chemother 38:738-741.
5. Kenny, G. E. 1991. Mycoplasmas, p. 478-482. 1263-1264. 1280. In A. Balows, W. J. Hausler, Jr , K. L. Herrmann, H. D. Isenberg, and H. J. Shadomy, (ed.), Manual of clinical microbiology, 5th ed. American Society for Microbiology, Washington, D.C.
6. Kenny, G. E., and F. D. Cartwright. 1991. Susceptibility of Mycoplasma pneumoniae to several new quinolones, tetracycline, and erythromycin. Antimicrob. Agents Chemother. 35:587-589
7. Kenny, G. E., and F. D. Cartwright. 1993. Susceptibilities of Mycoplasma kominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC 17116. Antimicrob. Agents Chemother. 37:1726-1727.
8. Kenny, G. E., and F. D. Cartwright. 1995. Susceptibilities of Mycoplasma pneumoniae, Mycoplasma homines, and Ureaplasma urealyticum to a new quinolone: CP-99,219-27, abstr. F236, p. 154. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy American Society for Microbiology, Washington, D.C.
9. Kenny, G. E., T. M. Hooton, M. C. Roberts, F. D. Cartwright, and J. Hoyt. 1989. Susceptibilities of genital mycoplasmas to the newer quinolones as determined by the agar dilution method. Antimicrob. Agents Chemother. 33:103-107.
10. Tully, J. G., D. Taylor-Robinson, D. L. Rose, R. M. Cole, and J. M. Bove. 1983. Mycoplasma genitalium, a new species from the human urogenital tract. Int. J. Syst Bacteriol. 33:387-396.
11. Waites, K. B., and G. H. Cassell. 1994. Clinical applications of fluoroquinolones for genital mycoplasmal infections. Infect. Med 1994:71-80, 88.